Aromatase inhibitors may be used to prevent or delay epiphysial closure and thereby increase adult height. They may be used to increase gonadotropin secretion and thereby stimulate Leydig and Sertoli cell function. As a result an inappropriate amount of aromatase was expressed in adipose tissue of the affected subjects.
Letrozole had better clinical pregnancy, live birth, and miscarriage rates than natural or hormone replacement therapy (HRT) 45-46. Additionally, a study found that letrozole co-treatment could improve pregnancy outcomes by reversing the expression of anb3 integrin in the endometrium . Compared to clomiphene citrate, letrozole increases pregnancy rates for superovulation in women with unexplained infertility.
LH and FSH are the two important gonadotropins that signal the testes to begin production of Testosterone, while SHBG is a protein that binds to androgens and renders them inactive (in much the same way aromatase inhibitors will bind to the aromatase enzyme and render it inactive). In this study, LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone) had increased, while SHBG (Sex Hormone Binding Globulin) had decreased. One particular study evaluated an elderly male exhibiting sexual dysfunction issues resultant of low endogenous androgen production that was administrated with Letrozole doses, and the study concluded that Testosterone levels were restored normal physiological levels and sexual function was restored. Letrozole in particular in many studies has demonstrated to hold the capability to raise Testosterone levels through the reduction of Estrogen. It is important to remember that medically, Letrozole is approved for use in post-menopausal females only, who possess a very different shift in hormone levels compared to pre-menopausal females.
Two aromatase-deficient men had a brother who also suffered from infertility despite a normal aromatase genotype, suggesting an unrelated second condition. It is synthesized from testosterone or estrone via aromatase or 17β-hydroxysteroid dehydrogenase, respectively. These promoters are under the influence of different hormones and growth factors such as gonadotropins (gonadal promoter II) and interleukin-6, interleukin-11 and tumor necrosis factor-a (adipose/bone promoter I.4; for review see ). This review will discuss the potential targets and the evidence for the use of aromatase inhibitors in men and adds more recent data to the text of an earlier review on this subject . Long-term efficacy and safety of the use of aromatase inhibitors has not yet been established in males, however, and their routine use is therefore not yet recommended. However, free testosterone frequently rose to supraphysiological levels. Letrozole has been reported as a treatment option for male infertility since 2011.
These authors used ammonium sulfate precipitation to measure bioavailable estradiol levels whereas if they had calculated bioavailable estradiol levels using the popular Sodergard equation 79,80 their proposed threshold may have been as high as 75 pM. Thresholds should be interpreted with great caution because they rely heavily on the methods used to measure total or bioavailable estradiol levels. Aromatase inhibitors are widely prescribed for hormone-responsive breast carcinoma in postmenopausal women. The combination of testosterone and letrozole, therefore, was tested in boys with constitutional delay of puberty.
Though not FDA approved for treatment of male hypogonadism selective estrogen receptor modulators have gradually made their way into the mainstream of treatment modalities for male infertility and hypogonadism. The medications reviewed in this manuscript raise endogenous testosterone levels through the hypothalamic pituitary axis and are considered off label use by the FDA. Causes of primary hypogonadism include testicular infection, infarction, testicular cancer, gonadotoxic medications including chemotherapy, orchiectomy, trauma, and Klinefelter’s syndrome. Hypogonadism, a disease state characterized by low testosterone levels, is typically treated with testosterone replacement when the etiology is secondary to testicular pathologies.
Breast cancer treatments can initiate sterility, menopause, and worsen menopausal symptoms. There were no neurologic or cardiac complications from the chemotherapy. Response to therapy was determined by change in tumor volume. Aromatase inhibitors are not effective for the treatment of gynecomastia in pubertal boys and have limited efficacy for the prevention of gynecomastia in bicalutamide-treated men with prostate cancer. The same group of investigators concluded that there were no effects of letrozole on cognitive performance could be detected in a group of prepubertal boys .
The decline of testosterone levels has been implicated in the pathogenesis of physical frailty in older men. It is well known from experimental evidence and from clinical observations that estradiol has powerful effects on gonadotropin release in men. These case reports illustrate the important contribution of estrogens to male health and identify the possible indications and risks of aromatase-inhibitor treatment in men.

Gênero: Fêmea

Links sociais